Fish Vaccine Market Scope
Immunization of fish is often used for many years and is widely recognised as an efficient technique of preventing a variety of bacterial and viral infections. Vaccination initiatives contribute to global aquaculture's environmental, social, and economic sustainability. Traditionally, most licensed fish vaccines were inactivated microorganisms prepared with adjuvants and administered via immersion or injection. Subunit or recombinant DNA/RNA particle vaccines are examples of vaccinations made using modern vaccine technologies that target individual pathogen components. These cutting-edge technologies have been developed all around the world, and they appear to produce higher levels of immunity than traditional fish vaccines. Advanced technologies have showed significant promise for the future of aquaculture vaccines, and will give producers with health benefits as well as increased commercial potential.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
Key Companies Profiled | AquaTactics Fish Health (United States), Hipra (India), Ictyogroup (France), Intervet International B.V. (Netherlands), Microsynbiotix (Ireland), Nisseiken Co., Ltd. (Japan), Pfizer Inc. (United States), Kyoritsuseiyaku Corporation (Japan) and Tecnovax S.A. (Argentina) |
CAGR | 21.7% |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Fish Vaccine market throughout the predicted period.
AquaTactics Fish Health (United States), Hipra (India), Ictyogroup (France), Intervet International B.V. (Netherlands), Microsynbiotix (Ireland), Nisseiken Co., Ltd. (Japan), Pfizer Inc. (United States), Kyoritsuseiyaku Corporation (Japan) and Tecnovax S.A. (Argentina) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Veterquimica SA (Chile), Zoetis Inc. (United States), Merck KGaA (Germany) and Seppic (France).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Fish Vaccine market by Type , by Application (body in learning how to protect it from viruses) and Region with country level break-up.
On the basis of geography, the market of Fish Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2023.
Market Leaders and their expansionary development strategies
In December, 2018 - Aquaculture Acquired Assets of KoVax Ltd. (Israel based Vaccine Manufacturer). Phibro's Position in Fish Vaccine Discovery Is Strengthened, And Its Aquaculture Product Line Is Expanded. The R&D Team from KoVax Joined Phibro's Biological Segment, With the Goal of Developing a Pipeline of Novel Vaccines for The Aquaculture.
In April, 2021 - CIBA Launched India's First Homegrown Fish Vaccine for Viral Nervous Necrosis (VNN). CIBA-Nodavac-R is an Injectable Recombinant VNN Vaccine That Efficiently Protects Fingerlings from VNN Produced by Red-Spotted Grouper Nervous Necrosis Virus (RGNNV) And Prevents Vertical Transmission in Brooders.
Influencing Trend:
Emergence of Advance Fish Vaccine Techniques
Market Growth Drivers:
Prevalence of Infectious Diseases and Growing Aquaculture Industry
Challenges:
Fierce Competitive Pressure and High Initial Investment
Restraints:
Stringent Environmental Regulations
Opportunities:
Increasing Number of Artificial Fisheries Across Emerging Regions
Key Target Audience
Fish Vaccine Manufactures, New Entrants and Investors, Fish Vaccine Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others